Rosati G - Search Results

1

Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study.

Pinto C, Orlandi A, Normanno N, Maiello E, Calegari MA, Antonuzzo L, Bordonaro R, Zampino MG, Pini S, Bergamo F, Tonini G, Avallone A, Latiano TP, Rosati G, Cogoni AA, Ballestrero A, Zaniboni A, Roselli M, Tamberi S, Barone C. Pinto C, et al. Among authors: rosati g. J Clin Oncol. 2024 Apr 10;42(11):1278-1287. doi: 10.1200/JCO.23.01021. Epub 2024 Jan 5. J Clin Oncol. 2024. PMID: 38181312 Free PMC article. Clinical Trial.

2

A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer.

Rosati G, Rossi A, Reggiardo G, Manzione L. Rosati G, et al. Oncology. 2002;62(3):209-15. doi: 10.1159/000059567. Oncology. 2002. PMID: 12065867 Clinical Trial.

3

Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study.

Caponigro F, Rosati G, De Rosa P, Avallone A, De Rosa V, De Lucia L, Comella P, Comella G. Caponigro F, et al. Among authors: rosati g. Oncology. 2002;63(3):232-8. doi: 10.1159/000065470. Oncology. 2002. PMID: 12381902 Clinical Trial.

4

Subcutaneous granulocyte-macrophage colony-stimulating factor in mucositis induced by an adjuvant 5-fluorouracil plus leucovorin regimen. A phase II study and review of the literature.

Rossi A, Rosati G, Colarusso D, Manzione L. Rossi A, et al. Among authors: rosati g. Oncology. 2003;64(4):353-60. doi: 10.1159/000070293. Oncology. 2003. PMID: 12759532 Clinical Trial.

5

A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.

Rosati G, Tucci A, Rinaldi A, Colarusso D, Pizza C, Reggiardo G, Manzione L. Rosati G, et al. Oncology. 2004;66(5):371-8. doi: 10.1159/000079485. Oncology. 2004. PMID: 15331924 Clinical Trial.

6

Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.

Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Cartenì G, Agostara B, Pezzella G, Manzione L, Borsellino N, Misino A, Romito S, Durini E, Cordio S, Di Seri M, Lopez M, Maiello E, Montemurro S, Cramarossa A, Lorusso V, Di Bisceglie M, Chiarenza M, Valerio MR, Guida T, Leonardi V, Pisconti S, Rosati G, Carrozza F, Nettis G, Valdesi M, Filippelli G, Fortunato S, Mancarella S, Brunetti C; Gruppo Oncologico Dell'Italia Meridionale. Colucci G, et al. Among authors: rosati g. J Clin Oncol. 2005 Aug 1;23(22):4866-75. doi: 10.1200/JCO.2005.07.113. Epub 2005 Jun 6. J Clin Oncol. 2005. PMID: 15939922 Clinical Trial.

7

Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients.

Rosati G, Cordio S, Tucci A, Blanco G, Bordonaro R, Reggiardo G, Manzione L. Rosati G, et al. Oncology. 2005;69(2):122-9. doi: 10.1159/000087814. Epub 2005 Aug 23. Oncology. 2005. PMID: 16118508 Clinical Trial.

8

Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.

Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti P, Bonetti A, Negru ME, Tronconi MC, Luppi G, Silvano G, Corsi DC, Bochicchio AM, Chiaulon G, Gallo M, Boni L. Aschele C, et al. Among authors: rosati g. J Clin Oncol. 2011 Jul 10;29(20):2773-80. doi: 10.1200/JCO.2010.34.4911. Epub 2011 May 23. J Clin Oncol. 2011. PMID: 21606427 Clinical Trial.

9

Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study.

Rosati G, Cordio S, Aprile G, Butera A, Avallone A, Di Lucca G, De Pauli F, Parra HS, Reggiardo G, Bordonaro R. Rosati G, et al. Invest New Drugs. 2012 Oct;30(5):1978-83. doi: 10.1007/s10637-011-9721-6. Epub 2011 Jul 19. Invest New Drugs. 2012. PMID: 21769636 Clinical Trial.

10

XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study.

Rosati G, Avallone A, Aprile G, Butera A, Reggiardo G, Bilancia D. Rosati G, et al. Cancer Chemother Pharmacol. 2013 Jan;71(1):257-64. doi: 10.1007/s00280-012-2004-x. Epub 2012 Oct 26. Cancer Chemother Pharmacol. 2013. PMID: 23100174 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

449 results

Search Page